Tag:
Nexium
Latest Headlines
Latest Headlines
Rebates cut $40B off drugmakers' returns
In a fascinating look at one aspect of pharma pricing, Forbes' Matthew Herper explores the area of rebates, providing a chart of the biggest givebacks.
Can AstraZeneca continue to swear off major M&A?
Can AstraZeneca ( $AZN ) CEO David Brennan stick to his no-megadeals diet? Analysts are beginning to wonder, says Bloomberg, now that three of the company's promising drug candidates have stumbled. The
AstraZeneca cuts 1,150 U.S. jobs, adds on in China
It's becoming the fashion for drugmakers to announce job cuts in the U.S. and expansions in Asia in almost the same breath. Eli Lilly ( $LLY ) did it in fall 2009, saying it would cut 5,500 jobs in
Lipitor's $131B lifetime sales dwarf other megablockbusters
The names of the five best-selling drugs of all time aren't much of a surprise: Lipitor, Plavix, Zocor, Seretide/Advair, and Nexium. But what might be surprising are the figures attached. Pfizer's
Ranbaxy rolls out U.K.'s first Nexium generic
Ranbaxy Laboratories launched the U.K.'s first generic version of AstraZeneca's ( $AZN ) stomach drug Nexium. The brand is AZ's third-biggest seller, but it accounts for only $97 million in sales
Public Citizen asks FDA for black box on PPIs
Public Citizen is petitioning the FDA for a "black box" warning on common stomach acid drugs such as AstraZeneca's ( $AZN ) Nexium and Prilosec and Pfizer's ( $PFE ) Protonix. The consumer watchdog group
European regulators greenlight AZ's Nexium combo
AstraZeneca's ( $AZN ) Nexium-plus-aspirin combo, dubbed Axanum, got the nod from European regulators. The company says it's working to get the drug onto formularies there as soon as possible. Report
DoJ subpoenas AZ, Medco about four meds
AstraZeneca and Medco Health Solutions are under the Department of Justice's microscope. Prosecutors have subpoenaed the drugmaker and pharmacy benefits manager about their relationship, asking
Japan ushers in big meds from AZ, GSK, Merck
Japanese health regulators spread some happiness yesterday, granting marketing approval to several major Big Pharma products. AstraZeneca, GlaxoSmithKline, and Merck each got the nod for a key drug
AZ mulls next steps on Nexium patent
What's AstraZeneca to do about its Nexium patents? Even the company doesn't know yet, Dow Jones reports. In the wake of last Friday's decision from the European Patent Office, which invalidated and
